Evaluation of Toric Intraocular Lenses in Patients With Low Degrees of Astigmatism
Evaluation of Toric Intraocular Lenses in Patients With Low Degrees of Astigmatism
复制标题
低度散光患者环曲面人工晶状体的评价
DOI：
10.1097/apo.0000000000000112
复制
发表时间：
2015
影响因子：
4.4
通讯作者：
C. Hodge
中科院分区：
文献类型：
--
作者：
Lewis M Levitz;J. Reich;Kate Roberts;C. Hodge
目的探讨环状人工晶状体(IOL)治疗低度角膜散光的疗效。设计采用回顾性病例系列研究。方法回顾分析76例单焦点环状透镜(SN6AT2 Toric)和44例环状多焦点透镜(SND1T2+3.00)治疗低量散光患者的临床资料。分别于术前、术后3个月进行眼部评估。监测屈光状态和视力结果。结果单焦环切组屈光度小于0.25度的占69.7%，多焦环切组的屈光度小于0.25度占70.5%。两组术后屈光度均显著降低(P=0.001)。单焦(66.7%)和多焦(68.2%)患者裸眼远视力达到20/20或更高。结论这是第一篇研究低屈光度Toric人工晶状体在角膜柱面直径小于1.25D的患者中的应用的文章。在开发低屈光度环形人工晶状体之前，有低到中度散光的患者需要同时进行术中调整或其他形式的治疗，才能从白内障和人工晶状体手术中受益。有证据表明，Toric T2人工晶状体现在消除了这一障碍，提供了一致、准确的屈光和散光结果，并使这些患者能够通过跨IOL平台的单一治疗获得出色的结果。更大规模的研究将有助于巩固我们的成果。
Purpose This study aimed to describe the efficacy of toric intraocular lenses (IOLs) in patients with low degrees of corneal astigmatism. Design Retrospective case series was undertaken. Methods Patients with low amounts of corneal astigmatism who were treated with either a toric monofocal lens (SN6AT2 Toric, n = 76) or a toric multifocal lens (SND1T2 +3.00, n = 44) were reviewed. Eyes were evaluated preoperatively and 3 months postoperatively. Refraction and visual outcomes were monitored. Results Patients (69.7%) in the monofocal toric group obtained refractive cylinder less than 0.25 diopters (D) compared with 70.5% of the multifocal toric group. Both toric groups showed a statistically significant reduction in refractive cylinder after surgery (P = 0.001). Monofocal (66.7%) and multifocal (68.2%) toric patients achieved uncorrected distance visual acuity of 20/20 or better. Conclusions This represents the first article to investigate the use of low-power toric IOLs in patients with less than 1.25 D of corneal cylinder. Before the development of low-power toric IOLs, patients with low to moderate amounts of astigmatism required concurrent intraoperative adjustments or additional forms of treatment to benefit from cataract and IOL surgery. Evidence suggests that the toric T2 IOL now removes this barrier, providing consistent, accurate refractive and astigmatic results, and enables these patients to achieve excellent outcomes with a single treatment across IOL platforms. Larger studies will help to consolidate our results.